journal
MENU ▼
Read by QxMD icon Read
search

Thrombosis Research

journal
https://www.readbyqxmd.com/read/29459247/an-exploratory-factor-analysis-of-inflammatory-and-coagulation-markers-associated-with-femoral-artery-atherosclerosis-in-the-san-diego-population-study
#1
Natalie Suder Egnot, Emma Barinas-Mitchell, Michael H Criqui, Matthew A Allison, Joachim H Ix, Nancy S Jenny, Christina L Wassel
BACKGROUND AND AIMS: Several biomarkers of inflammation and coagulation have been implicated in lower extremity atherosclerosis. We utilized an exploratory factor analysis (EFA) to identify distinct factors derived from circulating inflammatory and coagulation biomarkers then examined the associations of these factors with measures of lower extremity subclinical atherosclerosis, including the ankle-brachial index (ABI), common and superficial femoral intima-media thickness (IMT), and atherosclerotic plaque presence, burden, and characteristics...
February 13, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29459016/special-issue-late-consequences-of-venous-thromboembolism
#2
EDITORIAL
Susan R Kahn, Vittorio Pengo
No abstract text is available yet for this article.
February 13, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29438871/red-cell-distribution-width-as-a-predictor-of-1-year-survival-in-ischemic-stroke-patients-treated-with-intravenous-thrombolysis
#3
João Pinho, Sofia Alexandra Marques, Eduardo Freitas, José Araújo, Mariana Taveira, José Nuno Alves, Carla Ferreira
INTRODUCTION: Red cell distribution width (RDW) has been found to be a prognostic marker in vascular diseases. Increased RDW predicted mortality and outcome after ischemic stroke however, the underlying mechanisms are unclear. Our study aimed to clarify the relation of RDW with stroke severity and 1-year survival. MATERIAL AND METHODS: Single-centre retrospective cohort study based on a prospective database of consecutive patients with acute anterior circulation ischemic stroke treated with intravenous thrombolysis (IVT) in a 9-year period...
February 7, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407631/genetic-mutations-in-pear1-associated-with-cardiovascular-outcomes-in-chinese-patients-with-acute-coronary-syndrome
#4
Xiao-Yan Nie, Jun-Lei Li, Si-Bei Qin, Yu Fu, Guang-Kai Liang, Lu-Wen Shi, Hong Shao, Jian Liu, Yun Lu
OBJECTIVE: To investigate the association between PEAR1 (platelet endothelial aggregation receptor-1) polymorphisms and cardiovascular outcomes in acute coronary syndrome (ACS) in patients treated with aspirin and clopidogrel. METHODS: We genotyped eight common PEAR1 SNPs (rs2768759, rs12566888, rs12041331, rs11264579, rs2644592, rs822441, rs822442, and rs4661012), also CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893) in 196 Chinese patients with ACS. We assessed the association between PEAR1 polymorphisms and platelet inhibition rate (PIR) measured by thromboelastography (TEG)...
February 1, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407630/low-molecular-weight-heparin-treatment-for-portal-vein-thrombosis-in-liver-cirrhosis-efficacy-and-the-risk-of-hemorrhagic-complications
#5
Jihyun Kwon, Youngil Koh, Su Jong Yu, Jung-Hwan Yoon
INTRODUCTION: Portal vein thrombosis (PVT) is a well-known complication in patients with liver cirrhosis (LC). The aim of this study is to investigate the outcomes of cirrhotic patients with PVT treated with low-molecular-weight heparin (LMWH). METHOD: Ninety-one LC patients with PVT were treated with dalteparin or enoxaparin for six months. Patients with major bleeding during the last three months, severe thrombocytopenia, or impaired renal function were excluded...
February 1, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407628/intraplatelet-reactive-oxygen-species-ros-correlate-with-the-shedding-of-adhesive-receptors-microvesiculation-and-platelet-adhesion-to-collagen-during-storage-does-endogenous-ros-generation-downregulate-platelet-adhesive-function
#6
Mehran Ghasemzadeh, Ehteramolsadat Hosseini, Zahra Oushyani Roudsari, Parvin Zadkhak
Platelets storage lesion is mainly orchestrated by platelet activating signals during storage. Reactive oxygen species (ROS) are being considered as important signaling molecules modulating platelet function while their production has also been shown to be augmented by platelet activation. This study investigated to what extent endogenous ROS generation during platelet storage could be correlated with platelet receptor shedding, microvesiculation and adhesive function. 10 PRP-platelet concentrates were subjected to flow cytometry analysis to examine the generation of intraplatelet ROS on days 1, 5 and 7 after storage...
February 1, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407627/transition-of-care-for-patients-with-venous-thromboembolism-rationale-design-and-implementation-of-a-quality-intervention-project-conducted-at-american-thrombosis-and-hemostasis-network-athn-affiliated-sites
#7
Julie Jaffray, Madhvi Rajpurkar, Anjali Sharathkumar, Kavita Patel, James Munn, Dunlei Cheng, Ellen McCarthy, Maria DeSancho
INTRODUCTION: Medication errors frequently occur during transition from the inpatient to outpatient setting. Anticoagulants are associated with serious medical errors, including major bleeding. Standardized transition of care (TOC) techniques in patients with venous thromboembolism (VTE) have not been developed. METHODS: This ongoing project conducted by the American Thrombosis and Hemostasis Network (ATHN) aims to improve TOC for newly diagnosed VTE patients on anticoagulation from the inpatient to outpatient setting, and identify characteristics of patients on direct oral anticoagulants (DOACs) and their TOC...
February 1, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29427868/acquired-factor-v-deficiency-in-a-patient-with-myeloma-and-amyloidosis
#8
LETTER
J K S Quek, W H Wong, C W Tan, Mya Hae Tha, C Nagarajan, L H Lee, H J Ng
INTRODUCTION: We describe our experience with managing an unusual case of acquired Factor V deficiency (aFVd) in a myeloma patient with demonstrated amyloidosis. METHODS: Following diagnosis, records of previous investigations were sought. Specific clotting factors and inhibitors were tested. The clinical progress and treatment response measured by serial factor V levels and coagulation parameters was then prospectively tracked. RESULTS: A 57 year-old woman presented with spontaneous right knee haemarthrosis in association with bilateral symmetrical polyneuropathy and proteinuria...
January 31, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407626/laboratory-biomarkers-for-venous-thromboembolism-risk-in-patients-with-hematologic-malignancies-a-review
#9
REVIEW
B T Samuelson Bannow, B A Konkle
INTRODUCTION: Despite high rates of venous thromboembolism (VTE) among patients with hematologic malignancies, few tools exist to assist providers in identifying those patients at highest risk for this potentially fatal complication. Laboratory biomarkers, such as d-dimer, have demonstrated utility in some clinical settings to distinguish patients at increased risk. MATERIALS AND METHODS: We performed a systematic review of the literature utilizing search terms including "biomarker", "venous thromboembolism", "hematologic malignancy", "lymphoma", "myeloma" and "leukemia" in the Medline database...
January 31, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407625/effectiveness-and-safety-of-outpatient-rivaroxaban-versus-warfarin-for-treatment-of-venous-thromboembolism-in-patients-with-a-known-primary-hypercoagulable-state
#10
Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, William L Baker, Jan Beyer-Westendorf
INTRODUCTION: Screening for primary hypercoagulable states (PHSs) in venous thromboembolism (VTE) patients was not mandated in the EINSTEIN trials; and therefore, few patients with a known PHS were available for analysis. We sought to assess the effectiveness and safety of rivaroxaban versus warfarin for treatment of VTE in patients with a known PHS. METHODS: Using MarketScan claims data from 1/2012-9/2015, we identified adults with a primary diagnosis of VTE during a hospitalization/emergency department visit (the index event), with ≥180-days of continuous insurance coverage prior to the index event, a documented diagnosis for a PHS and newly-initiated as an outpatient on rivaroxaban or warfarin within 30-days of the index VTE...
January 31, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407624/initial-strides-for-invent-vte-towards-global-collaboration-to-accelerate-clinical-research-in-venous-thromboembolism
#11
Marc Rodger, Nicole Langlois, Saskia Middeldorp, Susan Kahn, Per Morten Sandset, Timothy Brighton, Menno Huisman, Guy Meyer, Stavros Konstantinides, Walter Ageno, Pierre Morange, David Garcia, Lisa Baumann Kreuziger, Laura Young, Nigel Key, Manuel Monreal, David Jiménez
Venous thromboembolism (VTE) represents a major global burden of disease and requires collaborative efforts to conduct large, high-quality investigator-initiated and academically sponsored studies addressing the most relevant clinical questions. Owing to increasing regulatory requirements, the highly competitive nature of peer-reviewed funding and costs associated with conducting large, multinational clinical trials, completing practice-changing research constitutes a growing challenge for clinical investigators...
January 31, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407623/prognostic-significance-of-electrocardiogram-at-presentation-in-patients-with-pulmonary-embolism-of-different-severity
#12
Franco Casazza, Ilaria Pacchetti, Eliana Rulli, Loris Roncon, Pietro Zonzin, Marco Zuin, Cecilia Becattini, Amedeo Bongarzoni, Luigi Pignataro
BACKGROUND: Several electrocardiographic (ECG) abnormalities have been described in patients with acute pulmonary embolism (PE), with discordant reportings about their prognostic value. METHODS: Consecutive patients with echocardiography performed within 48 h from admission and ECG at presentation, were included in this analysis. The primary study outcome was in-hospital death for high-risk patients and in-hospital death or clinical deterioration for intermediate-risk patients...
January 31, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407633/the-lectin-pathway-and-coagulation-in-lung-cancer-patients-undergoing-lobectomy-a-randomised-controlled-trial
#13
Julie Brogaard Larsen, Anne Troldborg, Thomas Decker Christensen, Christine Lodberg Hvas, Steffen Thiel, Anne-Mette Hvas
BACKGROUND: Lectin pathway proteases activate coagulation and may theoretically play a role in the increased thrombosis risk in cancer, which is especially high during surgery. AIMS: To investigate lectin pathway proteins during lung cancer surgery, the influence of low molecular weight heparin (LMWH) on lectin pathway proteins, and correlations between lectin pathway proteins and coagulation. METHODS: Fifty lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy were randomised to LMWH, n = 26, or no anticoagulant (control), n = 24...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407622/simple-method-for-removing-doacs-from-plasma-samples
#14
T Exner, N Michalopoulos, J Pearce, R Xavier, M Ahuja
AIM: To evaluate a simple method using an adsorbent product (DOAC Stop) for extracting direct oral anti-coagulants (DOACs) from plasmas. METHOD: DOAC Stop was tested on normal and a range of abnormal plasmas initially using activated partial thromboplastin time (APTT) tests and a more DOAC-sensitive Russells viper venom-based clotting test (DOAC Test). Further tests for prothrombin time/International Normalized Ratio (PT/INR), lupus anticoagulants, activated protein C (APC) resistance, antithrombin, plasminogen, protein C and S were carried out on various patient samples...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407621/endothelial-cell-functions-impaired-by-interferon-in-vitro-insights-into-the-molecular-mechanism-of-thrombotic-microangiopathy-associated-with-interferon-therapy
#15
Haiyan Jia, Craig Thelwell, Paula Dilger, Chris Bird, Sarah Daniels, Meenu Wadhwa
INTRODUCTION: Interferon (IFN)-α and IFN-β approved for treatment of chronic hepatitis C viral infection and multiple sclerosis respectively have been linked to thrombotic microangiopathy (TMA) affecting renal function. Since the molecular mechanisms underlying this severe complication remain largely unclear, we aimed to investigate whether IFN affects directly in vitro endothelial cell functions associated with angiogenesis and blood haemostasis, as well as endothelial cell-derived vasodilators of nitric oxide (NO) and prostacyclin...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407620/point-of-care-testing-poct-to-assess-drug-concentration-in-patients-treated-with-non-vitamin-k-antagonist-oral-anticoagulants-noacs
#16
S Padayattil Jose, A Banzato, P Carraro, A Haleh, K Rossi, G Nante, G Denas, G Zoppellaro, V Pengo
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) do not need routine laboratory monitoring but measurement of drug concentration is important in emergency conditions. Specific laboratory tests are not readily available or not implemented in every hospital. Point-of-Care Tests (POCT) may bridge this gap and be used as a bedside solution. OBJECTIVES: Feasibility of POCT to assess plasma levels of dabigatran, rivaroxaban and apixaban. PATIENTS/METHODS: Activated Coagulation Time-Low Range (ACT - LR) using a portable Hemochron Signature Elite for dabigatran and prothrombin time (expressed as INR) by Coaguchek XS Pro for rivaroxaban and apixaban were obtained at trough and peak in 136 consecutive patients taking NOACs (70 on dabigatran, 45 on rivaroxaban and 20 on apixaban)...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29407632/what-have-we-learned-from-real-world-noac-studies-in-venous-thromboembolism-treatment
#17
REVIEW
Jan Beyer-Westendorf
Venous thromboembolism (VTE) remains a substantial clinical and health-economic burden worldwide and effective anticoagulant treatment is necessary immediately after VTE is suspected to reduce short- and long-term VTE related morbidity and mortality. For decades, low molecular weight heparin (LMWH), fondaparinux and Vitamin K antagonists (VKAs) have been the standard of anticoagulant therapy for VTE patients but these treatment options had clinically relevant drawbacks and limitations. The introduction of non-VKA oral anticoagulants (NOACs) that specifically inhibit either thrombin or factor Xa have resolved many of these drawbacks because these new compounds exhibit a rapid onset and offset of action, fewer food and drug interactions and a predictable anticoagulant effect...
January 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29395243/risk-prediction-of-cancer-associated-thrombosis-appraising-the-first-decade-and-developing-the-future
#18
Alok A Khorana, Charles W Francis
Cancer-associated venous thromboembolism (VTE) has major consequences for patients, including morbidity and risk of mortality. However, there is substantial variation in risk depending on a multitude of clinical risk factors and many cancer patients are at low risk for VTE. This critical concept of risk variation has led to efforts to identify patients at high or low risk for developing VTE. Our research group and others have focused on understanding and predicting risk of cancer-associated VTE. This narrative review describe research efforts conducted over the past decade, beginning with the 2008 publication of the first validated risk assessment tool in this setting...
January 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29395241/anticoagulant-drug-choice-in-patients-who-have-had-bariatric-surgery-presently-doacs-are-not-the-preferred-choice
#19
EDITORIAL
Stephan Moll, Karlyn A Martin
No abstract text is available yet for this article.
January 25, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29395242/suitability-for-catheter-directed-thrombolysis-in-patients-with-acute-lower-extremity-deep-vein-thrombosis-according-to-various-international-consensus-guidelines
#20
LETTER
Adrian Stefanescu, Adriano Alatri, Daniel Périard, Nils Kucher, Lucia Mazzolai, Rolf P Engelberger
No abstract text is available yet for this article.
January 23, 2018: Thrombosis Research
journal
journal
22831
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"